Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.

The company will start a phase 2/3 trial of PF-08634404 in March.

New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.

Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.

But Tevimbra’s role looks shaky as adverse events loom.

But Enhertu is coming.

The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.

Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.

Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.